Ayse Durnali

Dr. Ayse Durnali


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2013 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ADAyse Durnali
Ayse Durnali
NANecati Alkis
Necati Alkis
SCSengul Cangur
Sengul Cangur
FYFisun Ardic Yukruk
Fisun Ardic Yukruk
AIAli Inal
Ali Inal
BOBerna Oksuzoglu
Berna Oksuzoglu

30 May 2012 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
ADAyse Durnali
Ayse Durnali
STSaadet Tokluoglu
Saadet Tokluoglu
NONuriye Ozdemir
Nuriye Ozdemir
MIMevlude Inanc
Mevlude Inanc
NANecati Alkis
Necati Alkis
A(Anatolian Society Of Medical Oncology (Asmo) Anatolian Society Of Medical Oncology (Asmo)
Anatolian Society Of Medical Oncology (Asmo) Anatolian Society Of Medical Oncology (Asmo)
Uterine sarcomas are a group of heterogenous and rare malignancies of the female genital tract and there is a lack of consensus on prognostic factors and optimal treatment. To perform a retrospective evaluation of clinicopathological characteristics, prognostic factors and treatment outcomes of 93 patients with uterine sarcomas who were diagnosed and treated at 4 different centers from November 2000 to October 2010. Of the 93 patients, 58.0% had leiomyosarcomas, 26.9% malignant mixed Mullerian tumors, 9.7% endometrial stromal sarcomas, and 5.4% other histological types. According to the last International Federation of Gynecology and Obstetrics (FIGO) staging, 43.0% were stage I, 20.4% were stage II, 22.6% were stage III and 14.0 % were stage IV. Median relapse free survival (RFS) was 20 months (95% confidence interval (CI), 12.4-27.6 months), RFS after 1, 2, 5 years were 66.6%, 44.1%, 16.5% respectively. Median overall survival (OS) was 56 months (95% CI, 22.5-89.5 months), and OS after 1, 2, 5 years was 84.7%, 78%, 49.4% respectively. Multivariate analysis showed that age≥60 years and high grade tumor were significantly associated with poor OS and RFS; patients administered adjuvant treatment with sequential chemotherapy and radiotherapy had longer RFS time. Among patients with leiomyosarcoma, in addition to age and grade, adjuvant treatment with sequential chemotherapy and radiotherapy after surgery had significant effects on OS. Uterine sarcomas have poor progrosis even at early stages. Prognostic factors affecting OS were found to be age and grade.

17 March 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
NSnadiye sever
nadiye sever
FŞFatih Şimşek
Fatih Şimşek
İOİlknur Deliktaş Onur
İlknur Deliktaş Onur
HAHayati Arvas
Hayati Arvas
TGTural Guliyev
Tural Guliyev
İBİbrahim Vedat Bayoğlu
İbrahim Vedat Bayoğlu
Background: Osteosarcoma is a rare but aggressive bone malignancy. Despite advances in multimodal therapy, survival remains suboptimal, highlighting the need for prognostic markers to guide treatment. Methods: This study included 162 osteosarcoma patients who received neoadjuvant chemotherapy followed by surgery between January 2009 and March 2024. Patients received either double (cisplatin + doxorubicin) or triple (MAP or PEI) chemotherapy. Survival analyses were conducted using Kaplan–Meier curves, log-rank tests, and Cox proportional hazards models. Results: The median age was 20 years (IQR: 18–29), and 53.1% were male. Patients who received triple chemotherapy regimens demonstrated significantly longer overall survival (OS) compared to those on doublet regimens. High tumor necrosis rates (>90%) and negative surgical margins were strongly associated with improved OS, while metastatic disease at diagnosis, elevated alkaline phosphatase (ALP), and male gender were linked to poorer survival. Multivariate analysis identified adjuvant therapy, age under 18, high necrosis rate, negative margins, and normal ALP as significant OS predictors. Conclusions: Triple-agent chemotherapy, necrosis rate ≥90 and negative surgical margins are strongly associated with prolonged survival in osteosarcoma. The key prognostic indicators such as ALP levels, surgical margins and age at diagnosis should guide personalized treatment strategies to improve outcomes in curable patients.

18 March 2015
Verified
Journal Article
Closed access
OBOznur Bal
Oznur Bal
UAUlku Yalcintas Arslan
Ulku Yalcintas Arslan
ADAyse Durnali
Ayse Durnali
UUUmmugul Uyetrk
Ummugul Uyetrk
ADAyse Demirci
Ayse Demirci
BOBerna Oksuzoglu
Berna Oksuzoglu

1 September 2020
Verified
Journal Article
Closed access
FYFATİH YILDIZ
FATİH YILDIZ
ADAyse Durnali
Ayse Durnali
EEEmrah Eraslan
Emrah Eraslan
AIAysegul Ilhan
Aysegul Ilhan
GTGulnihal Tufan
Gulnihal Tufan
BOBerna Oksuzoglu
Berna Oksuzoglu
Purpose: Germ cell tumors (GCTs) are rare and highly curable malignancies. However, salvage treatments for relapsed or refractory disease are needed in approximately 20-60% of the patients. As salvage therapy, autologous stem cell transplantation (ASCT) administered after high-dose chemotherapy (HDCT) may be a feasible option as well as standard dose chemotherapy (SDCT). This study aimed to evaluate the efficacy and toxicity of ASCT in salvage therapy of GCTs retrospectively. Materials and Methods: Male patients older than 18 years of age who underwent ASCT due to a relapsed/refractory GCT were included in the study. Results: The median age of 18 patients included in the study was 28 (19-46). The majority of patients (n:16, 88.8%) had non-seminomatous GCT histology. All of the patients had relapsed or refractory GCTs and received bleomycin, etoposide, cisplatin (BEP) combination therapy previously. Half of the patients were in the poor risk group. ASCT was administered as a second-line therapy in 14 (77.7%) patients and third-line therapy in four (22.2%) patients. There is no ASCT-related exitus. Febrile neutropenia (FN) developed in almost all patients. Complete response (CR) was obtained in 7 (38.8%) patients, partial response (PR) in four (22.2%) patients after ASCT. The 2-year PFS was 44.4% and the median PFS was 8.7 (2.7-12.6) months. Median OS was 22.7 (3.9-41.7) months and 3 years OS was 50.0%. Conclusion: In conclusion, ASCT was found to be an effective and safe treatment option in salvage therapy of GCT patients in our study.